Table 3.
Descriptive statistics and clinicopathologic characteristics for patients included in in silico analysis of KIFC1 expression and overall survival
| Variable | Level | Number | Percentage |
|---|---|---|---|
| Age (Range) | 20–29 | 1 | 0.5 |
| 30–39 | 4 | 1.9 | |
| 40–49 | 23 | 11.1 | |
| 50–59 | 84 | 40.4 | |
| 60–69 | 54 | 26 | |
| 70–79 | 40 | 19.2 | |
| 80–89 | 1 | 0.5 | |
| Unknown | 1 | 0.5 | |
| Cancer site | Primary | 154 | 74 |
| Metastasis | 50 | 24 | |
| Unknown | 4 | 1.9 | |
| FIGO Stage | I | 9 | 4.3 |
| II | 9 | 4.3 | |
| III | 126 | 60.6 | |
| IV | 10 | 4.8 | |
| Unknown | 54 | 26 | |
| Grade | 1 | 6 | 2.9 |
| 2 | 80 | 38.5 | |
| 3 | 120 | 57.7 | |
| Unknown | 2 | 1 | |
| Survival Status | Alive | 109 | 52.4 |
| Dead | 98 | 47.1 | |
| Unknown | 1 | 0.5 | |
| Recurrence | Recurrence | 154 | 74 |
| No Recurrence | 53 | 25.5 | |
| Unknown | 1 | 0.5 |